The history of the interest in glucose metabolism in malignantly transformed cells dates back to the pioneering studies of War burg (1) . These studies led to the statement (2), in 1956: "The era in which the fermentation of cancer cells, or its importance, could be debated is over and no-one today can doubt that we understand the origin of cancer cells if we know how their large fermentation originates, or to express it more fully, if we know how the damaged respiration and the excessive fermentation of cancer cells originates." Even at this time, doubts were expressed about the respiratory deficiency of tumor cells (3) .
More recent evidence has shown that alterations in glucose metabolism in tumor cells are, in fact, a consequence of a primary alteration in plasma membrane glucose transport (4) (5) (6) (7) (8) (9) (10) . The primary defect in malignantly transformed cells has been proposed to lie in altered membrane transport processes that lead to increased intracellular concentrations of growth-promoting nutrients (11, 12) . In early experiments the transport rates of exponentially growing tumor cells were compared with those of slower growing controls (5) . Thus some authors claimed that rapid growth, rather than malignancy, might be the primary cause of elevated glycolysis in tumor cells (13, 14) . In answer to this criticism, Weber et al. (7) have shown that chick embryo fibroblasts transformed with Rous sarcoma virus exhibit rates of hexose transport three to five times higher than the measured rate of transport in rapidly growing control cells.
Su bstantially increased aerobic glycolysis is observed in numerous other systems in which cells are stimulated to divide (5, (15) (16) (17) (18) and, therefore, is not exclusively associated with malignancy. In this article we shall review the alterations in glucose metabolism that occur in one of the most widely studied, nonmalignant cell proliferation responses. The small lymphocytes of the mammalian immune system respond to a wide range of specific antigenic stimuli by undergoing a series of morphologic and metabolic alterations that culminate in blast transformation and cell division. These changes normally occur in only a small percentage of cells in response to a specific stimulus. In 1960, Nowell (19) discovered that similar changes may be induced in a much larger percentage of lymphocytes by the plant lectin, phytohemagglutinin. Since this time, many substances with similar properties have been found and called "polyclonal ligands" or "nonspecific mitogens."
We will suggest that enhanced glucose metabolism is neither necessary nor sufficient for the initiation of proliferation in mitogen-stimulated lymphocytes and, as a corollary, that enhanced aerobic glycolysis is VOL. 62, NO. I. JANUARY 1979 3 neither a fundamental nor a necessary property of malignantly transformed cells. Nevertheless, an understanding of the control mechanisms that regulate glucose metabolism in lymphocytes gives some insight into potential sites of defective feedback control in malignantly transformed cells.
GLUCOSE METABOLISM IN TRANSFORMING LYMPHOCYTES
Most preliminary studies on glucose metabolism in transforming lymphocytes (20) (21) (22) (23) (24) were concerned with measurements of lactate production. In human peripheral blood lymphocytes, stimulation of lactate production by phytohemagglutinin ranged from 80 to 1,300%, depending primarily on the time of incubation with the lectin (20) . The possible close correlation between the time of onset of DNA synthesis and maximal rates of glycolysis was suggested by Roos and Loos (22). Later, Wang et al. (18) showed that lactate production exactly parallels the rate of DNA synthesis in concanavalin A-treated spleen cells and returns to basal levels when DNA synthesis is over. Increases in lactate production of 50-60-fold were observed at the time of maximal [3 H ]th ym id in e incorporation into DNA (18) .
Changes of a similar magnitude have been observed in rat thymocytes cultured for 48-72 hours in the presence of concanavalin A (Schweinberger F, Weidemann MJ: Unpublished data).
REGULATION OF LYMPHOCYTE GLYCOLYSIS
Several early suggestions were made that stimulated glycolysis was the result of de novo synthesis of glycolytic enzymes. Hedeskov (25) observed that puromycin inhibited lactate production induced by phytohemagglutinin in human lymphocytes. Inasmuch as rates of triosephosphate isomerization were six to seven times the rate of glucose phosphorylation and because earlier work suggested that glucose transport is not rate limiting for lymphocyte glycolysis (26) , Hedeskov (25) suggested that increased synthesis of hexokinase was responsible for the increase in glycolysis. A more thorough analysis of intermediate changes in phytohemaggl utinin-treated lymphocytes (20) showed that adenine nucleotides (ADP and ATP), hexose diphosphate, and triosephosphate levels were increased after 2 hours' incubation. Similar changes have been observed in virus-transformed cells (4) . Culvenor and Weidemann (23) performed crossover plots for the glycolytic intermediates in phytohemagglutinin-treated thymocytes after varying times of incubation. Their work suggested that the glucose carrier-hexokinase and the phosphofructokinase reactions were potentially regulatory steps undergoing "nearly simultaneous, or tightly sequential, activation following interaction of the cells with the mitogen."
To further differentiate between the hexokinase and glucose transport reactions, we developed an assay for the transport of 3-0-methylglucose (a nonphosphorylated gl ucose analog) across the thymocyte plasma membrane (27) . Several other methods have been published, and their development has allowed a very thorough characterization of the influx and efflux kinetics of the thymocyte glucose carrier (28) .
Preliminary experiments indicated that the glucose carrier was stimulated by mitogenic agents. With concanavalin A, a detectable stimulation was observed within 5 minutes. Maximal stimulation occurred after 30 minutes. The glucose transport reaction was shown to obey Michaelis-Menton kinetics, and concanavalin A increased the maximal velocity without altering the Michaelis constant (27) . A similar pattern of response has been reported for the alterations in glucose transport kinetics in malignantly transformed cells (5, 6) . The magnitude of the alteration in maximal velocity induced by concanavalin A was seldom more than twofold (27) . Experiments on the total equilibration of 3-O-methylglucose across the thymocyte plasma membrane revealed that a twofold increase was a substantial underestimate of the magnitude of the concanavalin A response. Two kinetic components of glucose transport were demonstrated in unfractionated rat thymocytes (29) , which corresponded to two cell types with differing transport rates (a 30-40-fold difference). The fast-transporting cells were identified by density fractionation (29) as lymphoblasts, which are rapidly dividing cells that make up 15-20% of the thymocyte population. Whitesell et al. (30) demonstrated that the addition of concanavalin A did not alter the half time of either kinetic component of glucose analog uptake, but it increased the percentage of the total water space accessible to the fast-transporting component. .Thus those cells that respond to concanavalin A rapidly acquire the kinetic characteristics of lymphoblasts. Concanavalin A substantially increases the percentage of cells in a thymocyte population that are rapidly labeled by radioactive glucose analog (30) . The results above suggest that concanavalin A causes a 30-40-fold increase in carrier activity and J NATL CANCER INST that this increase is a rapid, all-or-nothing response.
The glucose carrier is probably rate limiting for thymocyte glycolysis. This reaction has a maximal activity one order of magnitude lower than the next slowest glycolytic enzyme and is substantially displaced from equilibrium in situ (27) . In addition, stimulation and inhibition of the carrier (as measured by 3-0-methylglucose transport) cause an exactly equivalent stimulation or inhibition of the glycolytic pathway (27) .
CONTROL OF GLUCOSE TRANSPORT

Protein Synthesis
The effects of protein synthesis inhibitors on concanavalin A-stimulated glucose transport have been investigated (27) . Both puromycin and cycloheximide completely inhibited CC]leucine incorporation into protein in thymocytes and prevented the rapid (within 5 min) activation of this process by concanavalin A. Additionally, puromycin blocked the stimulation of glucose transport and glycolysis induced by concanavalin A. This glycolytic inhibition was not mimicked by cycloheximide, which suggests that the response to puromycin was not related to the inhibition of protein synthesis. Puromycin probably acts through an inhibition of cyclic AMP phosphodiesterase (27) , inasmuch as agents that elevate cyclic AMP prevent the response of lymphocytes to concanavalin A (31) . These data do not exclude the possibility that mitogenic stimuli cause de novo synthesis of the carrier in longer incubations. The levels of glycolytic enzymes undergo a parallel increase of 200-300% in transformed human lymphocytes after 72 hours (32) . Parallel increases in glycolytic enzyme levels have also been observed in virus-transformed rat kidney cells (9) . The results suggest coordinated control of the synthesis of glycolytic enzymes. Although the number of glucose carriers in the plasma membrane cannot be assayed yet, carrier activity falls in thymocytes by 30-50% in I hour in the presence of protein synthesis inhibitors (27) ; this finding suggests that the carrier is relatively rapidly turned over.
Calcium
Mitogenic stimuli cause an increase in calcium uptake by lymphocytes (33, 34) . Evidence for a role for Ca 2+ in the mitogenic process has come from two lines of research. Firstly, mitogenesis is blocked by chelation of Ca 2+ in the medium (34) . Secondly, substantial Ca 2+-dependent transformation may be achieved with the divalent cation ionophore A23187 (35-37). The ionophore has been shown to mimic the effects of concanavalin A on 3-0-methylglucose transport and glycolysis (31, 38, 39 
Sulfhydryl Groups
Czech (40) has studied the effects of various sulfhydryl reagents on the stimulation of the adipocyte glucose carrier by insulin. He has proposed a thiol redox model (41) for the regulation of glucose transport in which carrier activation by insulin involves the formation within the carrier of a disulfide bridge inaccessible to N-ethylmaleimide. He also proposes the existence of a carrier-deactivation mechanism that is sensitive to N-ethylmaleimide but not to SH reagents that do not cross the plasma membrane (Ellman's reagent) (40) . Pretreatment of rat thymocytes with Nethylmaleimide prevents the stimulation of the carrier by either concanavalin A or A23187 (39). If the alkylating reagent is added after concanavalin A, the mitogen response is enhanced. Thus the thiol redox model may be applicable to the activation of glucose transport by mitogens in lymphocytes.
ALTERED CHARACTERISTICS OF STIMULATED GLUCOSE CARRIER
The glucose carrier is altered in its sensitivity to temperature after stimulation by concanavalin A (27) . Arrhenius' plots for glucose transport by rat thyrnocytes are biphasic, with a point of inflection at 20°C. In concanavalin A-treated cells, the inflection is less sharp and occurs at a lower temperature (15°C), which suggests an alteration in the lipid environment of the carrier. Above the transition temperature (between 15 and 40°C), the activation energy of the glucose carrier is increased by concanavalin A (from 44 to 98 kj/mole).
The stimulated carrier also exhibits an altered sensitivity to two inhibitors of glucose transport (39). Phloretin is a competitive inhibitor with a K, of 9.0 J.l.M. Concanavalin A-treated cells are more sensitive to phloretin inhibition, with a reduction in the apparent «, to 5.1 J.l.M.
Cytochalasin B is a competitive inhibitor of glucose transport (4) and its inhibitory effects on lymphocyte transformation may be overcome by the addition of glucose (42). The stimulation by concanavalin A is selectively abolished by low concentrations of cytochalasin B (5-500 nv).
We have proposed that the activated form of the thymocyte glucose carrier is a disulfide-linked dimer. Concanavalin A causes a decrease in the number of titratable surface SH groups (43). This decrease has been localized to a single membrane protein, which we suggest may be the glucose carrier.
ROLE OF ENHANCED GLUCOSE METABOLISM IN CELL PROLIFERATION
It is generally accepted that glucose is required as an energy source for cell proliferation; e.g., in (32) , "increased carbohydrate metabolism is undoubtedly necessary to meet the energy requirements of the cell in going from the relatively dormant lymphocyte to the highly active lymphoblast." Studies with various metabolic inhibitors have suggested that both glycolysis and (24) . In the absence of added substrates, freshly prepared thymocytes produce large amounts of NH/, which indicates the net oxidation of endogenous amino acids. Glucose stimulates respiration and suppresses amino acid oxidation. Respiration (02 and CO 2 production) in the presence of glucose is stimulated further (10-I5%) by concanavalin A. This stimulation probably results from a specific 30-40% increase in pyruvate oxidation, which may, in turn, result from an activation of the mitochondrial enzyme pyruvate dehydrogenase by Ca 2 + (38). The increase in pyruvate oxidation represents an increase in the percentage contribution of glucose carbon to the respiratory fuel. The oxidation of acetoacetate is not affected by concanavalin A (24); this finding suggests that, in contrast to previous proposals (22), the mitogen does not activate the tricarboxylic acid cycle. We suggest that the major function of increased pyruvate oxidation is to spare endogenous amino acids and fatty acids as macromolecule precursors. This function may be replaced by any exogenous source of acetyl coenzyme A without affecting transformation. For example, ketone bodies, which strongly inhibit pyruvate oxidation, do not affect transformation (24) .
Most of the extra glucose taken up in concanavalin A-treated thymocytes is converted to lactate. However, concanavalin A also causes an increased flow of glucose carbon into the nucleic acid, protein, and lipid pools (24) . This increase is directly proportional to the rate of glucose uptake, which suggests that glucose carrier activity may regulate the supply of macromolecule precursors based on glucose carbon. One may assess the relevance of this observation to macromolecule synthesis by removing glucose from the medium, which prevents concanavalin A stimulation of lymphocyte RNA and DNA synthesis (44). This experimental approach may be quantified by the titration of eH]thymidine incorporation into concanavalin A-stimulated thymocytes with varying glucose concentrations (24) . Concentrations well below the Michaelis constant of the glucose carrier for its natural substrate [0.3 mM (27) ] are sufficient to allow a substantial stimulation of DNA synthesis. Thus concanavalin A-induced stimulation of glucose uptake is not a necessary signal for the initiation of DNA synthesis. The observation that 25 J.l.M glucose will support half-maximal rates of DNA synthesis also makes it extremely unlikely that glucose is required as an energy source, particularly because neither lactate nor 3-hydroxy butyrate can substitute for glucose in any way (24) . When the medium glucose concentration is supersaturating for the glucose carrier (> I mja), a further doubling in eH]thymidine incorporation is observed. This increase suggests a correlation between the increased rate of glucose uptake in concanavalin A-treated cells and maximal proliferation.
A clue to the role of glucose was provided by the observation (24) that inosine, which does not affect either stimulated or unstimulated glucose transport, suppresses the effect of added glucose on DNA synthesis. Studies on lymphocyte nucleotide metabolism have suggested that the de novo synthesis of purine bases is necessary for proliferation (45). This process may be inhibited by inosine (46). We suggest that the major function of enhanced glycolysis in proliferating cells is the maintenance of elevated levels of glycolytic intermediates as macromolecule precursors. This proposal may explain the elevated levels of phosphoribosylpyrophosphate (47) and of glycerol and glycerol phosphate (20) in mitogen-treated cells. Lymphocytes escape the effects of the glucose transport inhibitor, cytochalasin B, after only a few hours in the presence of a mitogen (48). This finding suggests the possibility that large stores of precursors are built up during the early Glphase of the cell cycle as a prelude to macromolecule synthesis.
RELEVANCE OF MITOGEN-INDUCED LYMPHO-CYTE PROLIFERATION TO AN UNDERSTANDING OF MALIGNANT TRANSFORMATION
"The discovery that the surface of normal cells during mitosis is in several ways analogous to that of transformed cells is enlightening, as it suggests the existence in the cell cycle of a critical switching point. We still do not understand how this switch operates, but it is important that there is a critical point in the cell cycle when any normal cell can either be steered toward quiescence or switched over toward malignant growth and transformation." (49) Lymphocytes stimulated by plant lectins undergo a discrete proliferative response (50) after which both elevated glucose metabolism and DNA synthesis return to basal levels (18) . The possibility that glucose transport is chronically stimulated in malignantly transformed cells has been considered elsewhere (51). Thus changes in glucose metabolism attributed to malignancy (7) may reflect asynchronous fluctuations in glucose metabolism in the normal cells that are absent in transformed cells. Our results indicate that enhanced glucose metabolism is neither necessary nor sufficient for the initiation of DNA synthesis. A similar conclusion has been reached with respect to the control of fibroblast proliferation (15) . Nevertheless, chronic carrier stimulation and uncontrolled growth are probably both consequences of a primary defect in malignantly transformed cells, and studies on the control of glucose transport may give insight into this defect.
Perdue (51) has suggested that tumor cell glucose transport may behave like insulin-stimulated transport that has been "locked in" with SH-blocking agents like N-ethylmaleimide, which prevent deactivation of the carrier upon removal of the hormone (41). One of the characteristics of locked-in transport in adipocytes is a substantially increased sensitivity to cytochalasin B (41). The concanavalin A-stimulated lymphocyte glucose carrier has increased sensitivity to cytochalasin B in the absence of N-ethylmaleimide (39). Thus there may be mechanisms for blocking the carrier-deactivation mechanism in cells committed to cell division or to long-term maintenance of high rates of glucose transport. If the active glucose carrier is in a disulfide form, a candidate for the role of deactivation mechanism is the enzyme NADPH-dependent protein disulfide reductase. The activity of this enzyme is increased in tumor cells and released into the extracellular fluid (52). Release may serve the double purpose of protecting the carrier from deactivation by exogenous free SH groups (52) and of expelling the deactivation mechanism from the cytoplasm. Tumor transplantability may be impaired by pretreatment with SH-blocking agents (52).
The involvement of Ca 2+ in the activation of the glucose carrier suggests a second possibility for chronic activation. Enhanced Ca 2+ uptake in mitogen-treated lymphocytes appears to be transient (39, 53) . Additionally, much of the Ca 2+ taken up by mitogenically stimulated lymphocytes has been shown to be rapidly sequestered by the mitochondria (54). Several studies have indicated abnormalities in plasma membrane (55) and mitochondrial (56) Ca2+ uptake in various types of tumor cells. The role of defective mitochondrial Ca 2+ uptake in the control of tumor metabolism has been discussed (56).
It has also been proposed that malignant transformation permanently modifies the adenylate cyclase of the plasma membrane and chronically lowers the levels of cyclic AMP. Several lines of evidence suggest a role for cyclic AMP in the control of cell proliferation (5) . The effects of exogenously added cyclic nucleotides on lymphocyte transformation are equivocal, inasmuch as the inhibition by cyclic AMP may be mimicked by numerous other cyclic and noncyclic nucleotides and nucleosides (33) . However, a number of agents that elevate cyclic AMP levels within cells (prostaglandins, catecholamines, and methyl xanthines) have also been shown to inhibit both overall proliferation (33) and the effects of mitogens on glucose transport (31) . This finding suggests that cyclic AMP may indeed have a role to play in feedback control of glucose transport.
Large transient rises in cyclic GMP have been observed in mitogen-stimulated lymphocytes and assigned a function in the control of proliferation (57). Of particular interest is a tumor-promoting phorbol ester, 12-0-tetradecanoylphorbol-13-acetate, that causes elevated levels of cyclic GMP, is mitogenic for human lymphocytes (58), and is a potent stimulator of thymocyte glucose transport (31) . Elevated guanylate cyclase activity and cyclic GMP accumulation have also been associated with carcinogenesis (59). Elevated levels of cyclic GMP and Ca 2+ may be related because the enzyme that synthesizes cyclic GMP, guanylate cyclase, is Ca 2+-sensitive (57).
AEROBIC GLYCOLYSIS AS A SITE OF ACTION FOR SPECIFIC ANTITUMOR AGENTS
The results we have presented above suggest fundamental similarities between mitogen-stimulated lymphocytes and malignantly transformed cells. These similarities may explain the immunosuppressive effect of many presently used cancer chemotherapeutic agents.
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The ideal anticancer agent is obviously one that interferes specifically with tumor growth without affecting the metabolism of nonmalignant cells. At present we know of no agent that specifically inhibits tumor glycolysis. Racker (60) has suggested that such a compound is the ATPase inhibitor, quercetin. However, we have shown that quercetin, like the closely related compound phloretin, is a competitive inhibitor of glucose transport and that mitogen-stimulated glucose transport is more sensitive to this inhibition than is unstimulated transport (Hume DA, Weidemann M], Ferber E: Manuscript in preparation).
A second reservation about the use of glycolytic inhibitors as antitumor agents is that, in normal cells, enhanced glucose metabolism is neither necessary nor sufficient for the initiation of proliferation, although it may permit an increase in the rate of DNA synthesis. Thus inhibition of the elevated rates of glycolysis in tumor cells may not necessarily produce coordinate reductions in their growth rate. Indeed, some transformed cell lines have been shown to exhibit normal or subnormal rates of glucose uptake (61).
Mitogen-stimulated lymphocytes have many advantages as a system for assessment of the "normal" control of cell growth. Lymphocytes do not have to be cultured in vitro prior to stimulation, and the mitogenic agents are simple and chemically well defined. The above discussion demonstrates the relevance of studies on the regulation of mitogen-induced lymphocyte proliferation to an understanding of malignancy and identifies Ca 2 +, cyclic AMP, and cyclic GMP as potentially important regulatory molecules.
